Massive Bio and GELL unite on oncology research, education and AI, but execution will determine whether the alliance expands trial access.
FDA approves MannKind Corporation’s Furoscix ReadyFlow for heart failure and CKD edema. See how the 10-second autoinjector may change care.
Incannex Healthcare begins DReAMzz screening to select an IHL-42X dose before Phase 3. Read what the sleep apnea study must prove.
Inhibikase Therapeutics wins FDA orphan status for IKT-001 as its pivotal PAH trial tests whether a prodrug can improve imatinib tolerability.
ANF Care is taking BioCoherence wearable discs to the United States, where evidence, claims and launch execution will shape adoption.
ResMed Inc. has agreed to sell its MatrixCare healthcare software business to Frazier Healthcare Partners for $490 million in cash, reversing part of a diversification strategy that began when the medical-device company acquired MatrixCare for $750 million in 2018. The transaction is expected to close during the first quarter of Resmed’s fiscal year 2027, subject
PDV MedTech and Corscience GmbH & Co. KG have formed a strategic partnership intended to give medical-device companies a more connected route from early product development through regulatory preparation, manufacturing scale-up and commercialization. The alliance combines Corscience’s engineering experience in complex and safety-critical systems with PDV MedTech’s manufacturing operations in the United States and its
Find out how FDA approval for Gilead Sciences’ Hepcludex could reshape chronic hepatitis delta virus treatment in the U.S.